Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone.
Kuloglu
M
M
Ekinci
O
O
Caykoylu
A
A
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D002065:Buspirone / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D011569:Psychiatric Status Rating Scales; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D012720:Severity of Illness Index; D020186:Sleep Bruxism / Q000139:chemically induced*; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D002065:Buspirone; D003511:Cyclohexanols; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride